Benchmark analyst Mike Hickey downgraded KushCo Holdings to Speculative Buy from Buy with a price target of $5, down from $7, as he suspects the unexplained vape related lung illness should challenge the company's near-term financial performance. He sees near-term pressure from cannabis operators slowing vape hardware purchases to minimize inventory risk, the potential for bans on the sale of vaping products and believes cannabis consumers will show caution as health officials investigate, said Hickey, who remains positive on KushCo over the long-term.